Main Article Content
Background and Objectives: Prostate cancer is an ever-increasing global incidence and has become the fifth leading cause of cancer-related mortality in men. A significant number of patients with prostate cancer develop metastatic castration-resistant prostate cancer (mCRPC). There are a few second-line treatment options for patients with post-docetaxel mCRPC. This systematic review aimed to assess the cost-effectiveness of cabazitaxel for the treatment of mCRPC.
Materials and Methods: Electronic bibliographic databases including: PubMed/Medline, NICE, CRD, and Scopus were searched in January 2018 for identifying full economic evaluations published in English and Persian. The risk of assessment bias and descriptive analyses of individual studies’ findings were presented.
Results: Three articles that fulfilled the inclusion criteria were included in the current study. All the included records had a reasonable quality. Cabazitaxel was not recommended as the most cost-effective option for the treatment of docetaxel-refractory mCRPC. Abiraterone acetate and radium-223 were the recommended cost-effective treatments for mCRPC treatment.
Conclusion: We found that, in general, while cabazitaxel had equal or slightly higher improvement in Quality-adjusted Life Year (QALY) as compared to the alternatives, it incurred a high cost. Despite the inclusion of a few studies in this review, cabazitaxel was not found to be a cost-effective option. Therefore, we recommend full economic evaluations to be conducted in this area.
WHO. Cancer; 2018.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E. Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. The Journal of Urology. 2018; 199(5):1224-1232.
Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: A review. Jama. 2017;317(24):2532-2542.
Kirby M, Hirst C, Crawford E. Characterising the castration‐resistant prostate cancer population: A systematic review. International Journal of Clinical Practice. 2011;65(11):1180-1192.
Guinney J, Wang T, Laajala TD, et al. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: Development of a prognostic model through a crowdsourced challenge with open clinical trial data. The Lancet. Oncology. 2017;18(1):132-142.
Catalona WJ. Prostate Cancer Screening. The Medical clinics of North America. 2018;102(2):199-214.
Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. International Journal of Urology: Official Journal of the Japanese Urological Association. 2018;25(6):524-531.
Vignani F, Bertaglia V, Buttigliero C, Tucci M, Scagliotti GV, Di Maio M. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer treatment Reviews. 2016;44:61- 73.
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine. 2004;351(15):1502-1512.
De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. The Lancet. 2010;376(9747): 1147-1154.
Paller CJ, Antonarakis ES. Cabazitaxel: A novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Design, Development and Therapy. 2011; 5:117-124.
Pezaro CJ, Omlin AG, Altavilla A, et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. European Urology. 2014;66(3): 459-465.
Al Nakouzi N, Le Moulec S, Albiges L, et al. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. European Urology. 2015;68(2):228-235.
Turpin A, Pasquier D, Massard C, Berdah JF, Culine S, Penel N. First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices. Bulletin du Cancer. 2017;104(6):552-558.
Gillessen S, Attard G, Beer TM, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology. 2018;73(2):178-211.
Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ. Systemic therapy in men with metastatic castration-resistant prostate cancer: A systematic review. Clinical oncology (Royal College of Radiologists (Great Britain)). 2013;25(7):406-430.
Suner A, Aydin D, Hacioglu MB, et al. Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology). European Review for Medical and Pharmacological Sciences. 2016; 20(7):1238-1243.
Parente P, Ng S, Parnis F, Guminski A, Gurney H. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program. Asia-Pacific Journal of Clinical Oncology. 2017; 13(6):391-399.
Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Cost Effectiveness and Resource Allocation. 2013;11(1):6.
Dissemination UoYCfRa. Systematic Reviews: CRD's guidance for undertaking reviews in health care. York: University of York; 2009.
Wilson L, Tang J, Zhong L, et al. New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions? Journal of Oncology Pharmacy Practice. 2014;20(6):417-425.
Peters ML, de Meijer C, Wyndaele D, et al. Dutch economic value of radium-223 in metastatic castration-resistant prostate cancer. Applied health economics and health policy. 2018;16(1):133-143.
Zhong L, Pon V, Srinivas S, et al. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: A cost-effectiveness analysis. PloS One. 2013;8(5):e64275.
Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology. 2012;13(10):983-992.
Sonpavde G, Bhor M, Hennessy D, et al. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clinical Genitourinary Cancer. 2015;13(4):309-318.
Gillessen S, Omlin A, Attard G, et al. Management of patients with advanced prostate cancer: Recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology. 2015;26(8):1589-1604.
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine. 2012; 367(13):1187-1197.
Badrising S, van der Noort V, van Oort IM, et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer. 2014; 120(7):968-975.
Hoskin P, Sartor O, O'Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. The Lancet Oncology. 2014;15(12):1397-1406.
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine. 2013;369(3):213- 223.
Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: A potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Management and Research. 2013;5:1.